financetom
Business
financetom
/
Business
/
Papa John's focused on executing its strategy but open to alternatives, CEO says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Papa John's focused on executing its strategy but open to alternatives, CEO says
Nov 6, 2025 6:54 AM

NEW YORK (Reuters) -Papa John's CEO Todd Penegor on Thursday said the U.S. pizza chain is focusing on executing its strategy to drive value, but noted it would consider alternatives if they were available.

Penegor, speaking in an earnings call after Papa John's missed its third-quarter earnings estimates, promised a host of improvements, including cost cuts and new side dishes and then addressed what he called "M&A rumors" after Reuters reported this week that a bid to take the company private had been withdrawn.

He acknowledged that softer consumer spending is weighing on quick-serve restaurants, but that the company is "positioning Papa John's to compete better in 2026." He said it is working on transforming the brand and fueling sustainable, profitable sales growth in the future.

The company cut its 2025 sales outlook because it now expects North American sales to be down 2% to 2.5% for the year, after an earlier forecast of being flat to up 2%.

Private equity firm Apollo Global withdrew its offer to take Papa John's private at $64 a share on concerns about consumer sentiment and the pizza chain's ability to navigate the weaker outlook, sources familiar with the matter told Reuters. The deal would have valued the company at $2.1 billion.

Investors had hoped Penegor would address speculation about a possible deal. He said if there were an alternative to the company's strategy, management and the board would "fully consider it."

Papa John's shares were down more than 5% in pre-market trading after 5% and 10% drops on Wednesday and Tuesday, respectively. The company's stock has dropped nearly 20% in the last five days and is down 28% in the last 12 months.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved